Welcome to our dedicated page for Marimed SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MariMed Inc. filings document formal disclosures for a cannabis consumer products and retail operator, including annual-meeting governance, operating results and material capital-structure agreements. Recent Form 8-K reports furnish quarterly and annual financial results and describe the restructuring of the company's Series B Convertible Preferred Stock obligation, including related debt and equity components.
Proxy materials disclose stockholder meeting procedures and board-governance matters. The filings also identify MariMed's emerging growth company status and provide public records for transactions, obligations and reporting events connected to its cannabis brand, wholesale distribution and dispensary operations.
MARIMED INC. President and CEO Jon R. Levine reported equity compensation activity involving company common stock and restricted stock units. He exercised 46,875 RSUs into an equal number of common shares, and 16,243 shares were withheld by the company to cover tax obligations related to this vesting.
Following these transactions, Levine directly held 21,354,861 shares of common stock. An additional 6,684,640 shares are held by the Jon Levine Family Trust for the benefit of his spouse and children, for which he disclaims beneficial ownership. After this vesting, 140,625 RSUs from the November 29, 2024 grant remain outstanding, scheduled to vest in three equal installments on November 29, 2026, May 29, 2027 and November 29, 2027.
MARIMED INC. Chief Commercial Officer Ryan Crandall reported routine equity compensation activity involving restricted stock units. On May 29, 2026, RSUs converted into 37,500 shares of common stock on a one-for-one basis, increasing his direct holdings to 917,134 shares.
To cover tax obligations from this vesting, 12,994 shares of common stock were withheld by the company at a price of $0.0805 per share. Following the transaction, Crandall also held 112,500 unvested RSUs that are scheduled to vest in three equal installments on November 29, 2026, May 29, 2027, and November 29, 2027, under an existing award agreement.
MariMed Inc. President and CEO Jon R. Levine reported open-market purchases of 60,000 shares of common stock on May 22, 2026. The buys were executed at prices of $0.0745, $0.0750, and $0.0767 per share. Following these purchases, he directly owns 21,307,986 common shares.
An additional 6,684,640 common shares are held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children. Levine disclaims beneficial ownership of the trust-held shares, meaning they are attributed to the trust rather than to him personally.
MariMed Inc. President and CEO Jon R. Levine reported an open-market purchase of 40,000 shares of common stock at $0.075 per share. Following this trade, he owns 21,247,986 shares directly. A separate 6,684,640 shares are held by the Jon Levine Family Trust for his spouse and children, which he disclaims as beneficially owned.
MariMed Inc. reported modest revenue growth but remained unprofitable for the quarter ended March 31, 2026. Revenue rose to $39.5 million from $37.9 million a year earlier, driven by both retail and wholesale cannabis product sales. Despite higher sales, the company posted a net loss of $3.8 million, an improvement from a $5.5 million loss in the prior-year quarter, as operating income turned slightly positive but interest and tax expense remained heavy.
Adjusted EBITDA increased to $3.6 million from $2.5 million, reflecting stronger underlying operations. Cash, cash equivalents and restricted cash totaled $7.9 million at quarter end, against $79.3 million of mortgages and notes payable. MariMed restructured its legacy Series B preferred obligation, cancelling the old shares and issuing $8.0 million in new notes plus 26.9 million new Series B preferred shares, recording a $0.7 million gain on extinguishment.
The company continues to operate as a multi-state cannabis producer and retailer and remains subject to cannabis-related tax rules. It fully accrued IRS tax assessments, including liens of approximately $6 million and $1 million, while disputing them through administrative processes.
MariMed Inc. reported first-quarter 2026 revenue of $39.5 million, up from $37.9 million a year earlier, driven by both retail and wholesale product sales. GAAP gross margin was 38.7%, with non-GAAP gross margin at 40.1%.
The company posted a GAAP net loss of $3.8 million, improving from a $5.5 million loss in 2025. Non-GAAP net loss was $3.2 million, while non-GAAP Adjusted EBITDA rose to $3.6 million and the Adjusted EBITDA margin increased to 9.1%.
MariMed highlighted a March 2 Restructuring and Exchange Agreement for $14.7 million of Series B convertible preferred stock, replacing a February 2026 mandatory conversion with longer-dated instruments and extending the weighted-average maturity to 4.6 years, which reduces near-term refinancing pressure and supports liquidity.
MariMed Inc. President and CEO Jon R. Levine reported routine equity compensation activity involving restricted stock units. On May 7, 2026, RSUs converted into 75,000 shares of common stock. To cover tax obligations tied to this vesting, the issuer withheld 25,988 shares, a tax-withholding disposition rather than an open-market sale.
Following these transactions, Levine directly holds 21,207,986 shares of MariMed common stock. A separate family trust holds 6,684,640 shares for the benefit of his spouse and children, and he disclaims beneficial ownership of those trust-held securities.
MariMed Inc. is asking stockholders to elect four directors and to approve, on an advisory basis, the appointment of M&K CPAs PLLC as independent auditors for fiscal year ending December 31, 2026, at a virtual annual meeting on June 4, 2026.
Holders of 398,920,671 common shares as of April 10, 2026 may vote online, by phone or mail. The board has three fully independent committees, and non‑employee directors receive a $40,000 annual retainer plus 75,000 RSUs. Named executives are paid mainly in salary and equity awards under the 2018 Stock Award and Incentive Plan.
MariMed Inc. Chief Operating Officer Timothy Shaw received a grant of 170,625 Restricted Stock Units (RSUs). The RSUs convert to common stock on a one-for-one basis and vest in four equal installments on July 15, 2026, October 15, 2026, January 15, 2027 and April 15, 2027.
After this award, Shaw reports 9,357,700 shares of MariMed common stock held directly, plus 170,625 RSUs. An additional 2,000,000 shares are held indirectly by the Shaw Family Trust for his children, for which he disclaims beneficial ownership.